Physician profile
James J Bendell
NPI 1518071182
$21,351.63
in general payments reported to CMS, 2019-2025
27 companies · $9,704 in 2025
The $9,704 reported for 2025 was more than what 97% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $149 · 2021: $270 · 2022: $5,774 · 2023: $335 · 2024: $4,836 · 2025: $9,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $13K · Food and Beverage: $1,217 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Travel and Lodging: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $13,000.00 |
| Food and Beverage | $1,217.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Travel and Lodging | $156.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $18,656.44 | 2022-2025 | |
| Boston Scientific Corporation | $955.38 | 2019-2025 | Axonics |
| Abbvie INC. | $261.98 | 2019-2025 | Orilissa, Lo Loestrin Fe |
| Axonics, INC. | $212.20 | 2022-2023 | Axonics, Bulkamid |
| Mayne Pharma Commercial LLC | $163.83 | 2022-2024 | |
| Therapeuticsmd, INC. | $151.26 | 2019-2022 | |
| Pfizer INC. | $90.79 | 2021-2024 | |
| Coloplast Corp | $88.72 | 2024-2025 | |
| Allergan, INC. | $63.46 | 2019-2020 | |
| Scynexis, INC. | $63.41 | 2022 | |
| Avion Pharmaceuticals | $63.20 | 2019-2023 | Balcoltra |
| Myovant Sciences INC. | $54.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.82 | 2020-2022 | |
| Astellas Pharma US INC | $47.09 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $46.98 | 2023-2024 | Myfembree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $46.73 | 2023-2025 | Endosee, Mara Console |
| Amag Pharmaceuticals, INC. | $42.76 | 2019 | |
| Evofem Biosciences, INC. | $40.85 | 2021 | |
| Hologic Sales and Service, LLC | $39.58 | 2022-2023 | Aptima |
| Exeltis, USA INC. | $38.53 | 2020 | |
| Agile Therapeutics, INC. | $37.36 | 2022-2024 | Twirla |
| Lupin INC. | $35.53 | 2019 | |
| Mylan Pharmaceuticals INC. | $34.36 | 2021 | |
| Meditrina | $26.63 | 2023 | |
| Acessa Health INC. | $13.73 | 2019 | |
| Minerva Surgical, INC | $13.15 | 2019 | |
| Teleflex LLC | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bendell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.